Clinical Trial Update: Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating intra-dermal injections of DLX105 into lesional skin for patients with mild-to-moderate psoriasis vulgaris; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• DLX105

Snippet

Sponsor: Delenex Therapeutics AG | Conditions: Mild-to-moderate Psoriasis Vulgaris | Phase 1, Phase 2 | Status: COMPLETED